Neurogene Investor Relations Material
Latest events
Study Update
Neurogene
Q2 2025
11 Aug, 2025
Corporate Presentation
30 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neurogene Inc
Access all reports
Neurogene Inc. (NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Utilizing its proprietary transgene regulation technology, known as Expression Attenuation via Construct Tuning (EXACT), Neurogene aims to address high unmet medical needs that are not effectively treated by conventional gene therapies. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.
Key slides for Neurogene Inc
Study Update
Neurogene Inc
Corporate Presentation
Neurogene Inc
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
NGNE
Country
🇺🇸 United States